Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 02, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 4,650,000 ordinary shares.
- Repurchase Price: 1,146.8766 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 8.98% of total voting rights).
- Shares in Issue: 5,279,705,389 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 4,650,000 shares purchased on July 02, 2008. Consequently, the number of shares held in Treasury increased to 474,194,158. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding share buybacks.
Key Facts for Investor Verification
- Verify the total cost of the buyback by multiplying 4,650,000 shares by the price of 1,146.8766 pence.
- Confirm the updated share count of 5,279,705,389 in issue for calculating ownership percentages under disclosure rules.
- Note that the repurchased shares were cancelled, not held indefinitely as treasury stock, though the company continues to hold a significant block of treasury shares from previous transactions.